AR062569A1 - Proceso para la purificacion de las proteinas de fusion fc - Google Patents
Proceso para la purificacion de las proteinas de fusion fcInfo
- Publication number
- AR062569A1 AR062569A1 ARP070103816A ARP070103816A AR062569A1 AR 062569 A1 AR062569 A1 AR 062569A1 AR P070103816 A ARP070103816 A AR P070103816A AR P070103816 A ARP070103816 A AR P070103816A AR 062569 A1 AR062569 A1 AR 062569A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- seq
- fusion
- chromatography
- amino acids
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 12
- 102000004169 proteins and genes Human genes 0.000 title abstract 12
- 230000004927 fusion Effects 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 238000000746 purification Methods 0.000 title abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 238000004587 chromatography analysis Methods 0.000 abstract 3
- 238000005571 anion exchange chromatography Methods 0.000 abstract 2
- 238000005277 cation exchange chromatography Methods 0.000 abstract 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 2
- 101710120037 Toxin CcdB Proteins 0.000 abstract 1
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/24—Extraction; Separation; Purification by electrochemical means
- C07K1/26—Electrophoresis
- C07K1/28—Isoelectric focusing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Abstract
La presente solicitud se refiere a un proceso para la purificacion de una proteína de Fusion Fc que tiene un pI entre 6,9 y 9,5 proteína que comprende la cromatografía de afinidad de la proteína A o G, la cromatografía de intercambio de cation, la cromatografía de intercambio de anion y la cromatografía de hidroxiapatita. Reivindicacion 1: El método para purificar una proteína de Fusion Fc que tiene un punto de isoeléctrico (pI) de 6,9 a 9,5, que comprende los pasos siguientes: a) Someter un fluido que comprende dicha proteína de Fusion Fc a cromatografía de afinidad de la Proteína A o la Proteína G; b) Someter el eluato del paso (a) a la cromatografía de cambio del cation; c) Someter el eluato del paso (b) a la cromatografía de cambio del anion; d) Someter el flujo continuo del paso (c) a la cromatografía de hidroxiapatita y recolectar el eluato para obtener la proteína purificada de Fusion Fc. Reivindicacion 28: Una composicion purificada de la proteína de la Fusion Fc obtenida por un método segun cualquiera de las reivindicaciones anteriores, en donde la proteína de Fusion Fc comprende un polipéptido escogido de (a) aminoácidos 34 a 66 de la SEC ID N°: 2; (b) aminoácidos 71 a 104 de la SEC ID N°: 2; (c) aminoácidos 34 a 104 de la SEC ID N°: 2; (d) aminoácidos 30 a 110 de la SEC ID N°: 2; (e) de la SEC ID N°: 3; (f) de la SEC ID N°: 4; (g) un polipéptido codificado por un polinucleotido que hibridiza al complemento de la SEC ID N°: 5 o 6 o 7 bajo condiciones sumamente rigurosas; y (e) una muteína de cualquiera de (c) , (d) , (e) o (f) teniendo por lo menos un 80% o 85% o 90% o 95 % de la identidad de la secuencia al polipéptido de (c) , (d), (e) o (f); en donde el polipéptido se une a por lo menos uno de Blys o APRIL, y en donde dicha composicion comprende menos del 1 % o menos del 0,5% de agregados de proteína, y en donde dicha composicion comprende menos de 1% o menos de 0,5% o menos de 0,1% de la proteína libre de Fc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119610 | 2006-08-28 | ||
| US84268206P | 2006-09-06 | 2006-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062569A1 true AR062569A1 (es) | 2008-11-19 |
Family
ID=37038258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103816A AR062569A1 (es) | 2006-08-28 | 2007-08-28 | Proceso para la purificacion de las proteinas de fusion fc |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100267932A1 (es) |
| EP (1) | EP2061802A1 (es) |
| KR (1) | KR20090058532A (es) |
| CN (1) | CN101541825B (es) |
| AR (1) | AR062569A1 (es) |
| AU (1) | AU2007291282B2 (es) |
| BR (1) | BRPI0716139A2 (es) |
| CA (1) | CA2661872A1 (es) |
| EA (1) | EA017733B1 (es) |
| IL (1) | IL197221A (es) |
| MX (1) | MX2009002013A (es) |
| NZ (1) | NZ574623A (es) |
| UA (1) | UA99263C2 (es) |
| WO (1) | WO2008025747A1 (es) |
| ZA (1) | ZA200900836B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| US8853371B2 (en) | 2006-10-19 | 2014-10-07 | Janssen Biotech, Inc. | Process for preparing unaggregated antibody Fc domains |
| US20080167450A1 (en) * | 2007-01-05 | 2008-07-10 | Hai Pan | Methods of purifying proteins |
| WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| RU2573894C2 (ru) | 2009-08-06 | 2016-01-27 | Дженентек, Инк. | Способ усовершенствования процесса удаления вирусов при очистке белков |
| US8536316B2 (en) | 2009-08-07 | 2013-09-17 | Emd Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
| EP3736338A1 (en) * | 2009-09-01 | 2020-11-11 | F. Hoffmann-La Roche AG | Enhanced protein purification through a modified protein a elution |
| EP2480561B1 (en) * | 2009-09-23 | 2016-07-13 | E. R. Squibb & Sons, L.L.C. | Cation exchange chromatography |
| US20130178608A1 (en) * | 2009-12-29 | 2013-07-11 | Samir Kulkarni | Protein purification by ion exchange |
| KR20120118065A (ko) * | 2010-02-12 | 2012-10-25 | 디에스엠 아이피 어셋츠 비.브이. | 단일 단위체 항체 정제 |
| WO2012030512A1 (en) * | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
| WO2012059308A1 (en) * | 2010-11-01 | 2012-05-10 | Dsm Ip Assets B.V. | Single unit ion exchange chromatography antibody purification |
| ES2784628T3 (es) | 2011-03-29 | 2020-09-29 | Glaxosmithkline Llc | Sistema de tampón para purificación de proteína |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| RS64791B1 (sr) * | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - vezujući proteini |
| WO2012176158A1 (en) * | 2011-06-24 | 2012-12-27 | Dr. Reddy's Laboratories Limited | Purification of chimeric protein |
| CN110551223A (zh) | 2011-06-28 | 2019-12-10 | 英伊布里克斯有限合伙公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
| DK2729482T3 (en) * | 2011-07-08 | 2018-05-07 | Merck Sharp & Dohme | PROCEDURE FOR CLEANING FC-FUSION PROTEIN |
| WO2013028330A2 (en) | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
| US20140301977A1 (en) * | 2011-11-02 | 2014-10-09 | Genentech, Inc. | Overload and elute chromatography |
| EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| CN104861060A (zh) * | 2014-02-21 | 2015-08-26 | 神州细胞工程有限公司 | 一种纯化凝血因子viii的方法 |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2017168296A1 (en) * | 2016-03-29 | 2017-10-05 | Navya Biologicals Pvt. Ltd | A process for purification of fc-fusion proteins |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| CN109311948B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 清洁和/或消毒分离基质的方法 |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2018031726A1 (en) | 2016-08-12 | 2018-02-15 | Bristol-Myers Squibb Company | Methods of purifying proteins |
| WO2018146067A1 (en) * | 2017-02-09 | 2018-08-16 | Bracco Suisse Sa | Process for the purification of soluble psgl-1 protein variants |
| CN107151673A (zh) * | 2017-03-10 | 2017-09-12 | 上海埃文生物科技有限公司 | 巴斯德毕赤酵母中人rank胞外段蛋白的表达纯化及其应用 |
| AU2018326458A1 (en) * | 2017-08-30 | 2020-02-20 | Ares Trading S.A. | Method for purifying proteins |
| US11964998B2 (en) | 2017-08-30 | 2024-04-23 | Fresenius Kabi Deutschland Gmbh | Method for purifying anti-IL-6 receptor antibodies |
| EP3746471A1 (en) * | 2018-01-31 | 2020-12-09 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| WO2021075526A1 (ja) * | 2019-10-17 | 2021-04-22 | Ｊｃｒファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質の製造方法 |
| CN114206924A (zh) | 2019-12-06 | 2022-03-18 | 瑞泽恩制药公司 | 抗vegf蛋白组合物及其制备方法 |
| KR20230025655A (ko) * | 2020-03-06 | 2023-02-22 | 알레타 바이오쎄라퓨틱스, 인크. | 암 치료용 조성물 및 방법 |
| CN116903727A (zh) | 2020-05-08 | 2023-10-20 | 高山免疫科学股份有限公司 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
| CN112574321B (zh) * | 2020-12-30 | 2023-10-20 | 上海赛金生物医药有限公司 | 一种捕获单克隆抗体-肿瘤坏死因子融合蛋白的亲和纯化方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| WO1994006476A1 (en) * | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| DK0659767T4 (da) * | 1993-12-27 | 2003-02-10 | Zlb Bioplasma Ag | Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dette |
| US6406901B1 (en) * | 1995-06-08 | 2002-06-18 | Immunex Corporation | TNF-a converting enzyme |
| NZ312285A (en) * | 1995-06-08 | 2001-04-27 | Immunex Corp | TNF-alpha converting enzyme (TACE) |
| US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| DE69936946T2 (de) * | 1998-05-06 | 2008-05-15 | Genentech, Inc., South San Francisco | Reinigung von Antikörpern durch Ionenaustauschchromatographie |
| MXPA02011130A (es) * | 2000-05-12 | 2003-03-10 | Amgen Inc | Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci. |
| RS20120253A1 (en) * | 2001-05-24 | 2013-02-28 | Zymogenetics Inc. | TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS |
| CA2469815C (en) * | 2001-12-21 | 2011-05-03 | Immunex Corporation | Methods for purifying protein |
| US7323553B2 (en) * | 2002-04-26 | 2008-01-29 | Genentech, Inc. | Non-affinity purification of proteins |
| ES2626268T3 (es) * | 2002-09-11 | 2017-07-24 | Chugai Seiyaku Kabushiki Kaisha | Método de purificación de proteínas |
| WO2004087761A1 (ja) * | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| BRPI0415887B1 (pt) * | 2003-10-27 | 2021-01-26 | Wyeth | métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
| CN1234725C (zh) * | 2004-04-07 | 2006-01-04 | 陈志南 | 一种高效快速纯化制备片段抗体的方法 |
| EP2388274A1 (en) * | 2005-06-17 | 2011-11-23 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A Beta antibodies |
| EP2114984A2 (en) * | 2007-01-17 | 2009-11-11 | Merck Serono S.A. | Process for the purification of fc-containing proteins |
-
2007
- 2007-08-27 US US12/377,119 patent/US20100267932A1/en not_active Abandoned
- 2007-08-27 KR KR1020097006448A patent/KR20090058532A/ko not_active Application Discontinuation
- 2007-08-27 NZ NZ574623A patent/NZ574623A/en not_active IP Right Cessation
- 2007-08-27 ZA ZA200900836A patent/ZA200900836B/xx unknown
- 2007-08-27 EA EA200970230A patent/EA017733B1/ru not_active IP Right Cessation
- 2007-08-27 WO PCT/EP2007/058886 patent/WO2008025747A1/en active Application Filing
- 2007-08-27 UA UAA200902919A patent/UA99263C2/ru unknown
- 2007-08-27 BR BRPI0716139-5A2A patent/BRPI0716139A2/pt not_active IP Right Cessation
- 2007-08-27 MX MX2009002013A patent/MX2009002013A/es active IP Right Grant
- 2007-08-27 AU AU2007291282A patent/AU2007291282B2/en active Active
- 2007-08-27 CN CN2007800319195A patent/CN101541825B/zh active Active
- 2007-08-27 CA CA002661872A patent/CA2661872A1/en not_active Abandoned
- 2007-08-27 EP EP07802924A patent/EP2061802A1/en not_active Withdrawn
- 2007-08-28 AR ARP070103816A patent/AR062569A1/es not_active Application Discontinuation
-
2009
- 2009-02-24 IL IL197221A patent/IL197221A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009002013A (es) | 2009-03-09 |
| EA017733B1 (ru) | 2013-02-28 |
| EA200970230A1 (ru) | 2009-08-28 |
| CA2661872A1 (en) | 2008-03-06 |
| AU2007291282A1 (en) | 2008-03-06 |
| IL197221A (en) | 2013-06-27 |
| EP2061802A1 (en) | 2009-05-27 |
| UA99263C2 (ru) | 2012-08-10 |
| WO2008025747A1 (en) | 2008-03-06 |
| KR20090058532A (ko) | 2009-06-09 |
| NZ574623A (en) | 2011-12-22 |
| ZA200900836B (en) | 2010-05-26 |
| US20100267932A1 (en) | 2010-10-21 |
| IL197221A0 (en) | 2009-12-24 |
| CN101541825B (zh) | 2013-08-14 |
| BRPI0716139A2 (pt) | 2013-09-17 |
| AU2007291282B2 (en) | 2011-10-20 |
| CN101541825A (zh) | 2009-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062569A1 (es) | Proceso para la purificacion de las proteinas de fusion fc | |
| FI2061803T4 (fi) | Process for the purification of fc-containing proteins | |
| Thomas et al. | Purification and characterization of acidic fibroblast growth factor from bovine brain. | |
| NO20076056L (no) | Fremgangsmater for rensing av FC region inneholdende proteiner | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| JP2011525523A5 (es) | ||
| ES2146600T3 (es) | Condroitinasa, procedimiento para su preparacion y composicion farmaceutica. | |
| DE60307262D1 (de) | Verfahren zur aufreinigung von albumin | |
| CA2264191A1 (en) | Recombinant toxin fragments | |
| US20130178608A1 (en) | Protein purification by ion exchange | |
| US11479578B2 (en) | Protein purification and virus inactivation with alkyl glycosides | |
| RU93046317A (ru) | Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции | |
| HRP20151086T1 (hr) | Metoda za proäśišä†avanje rekombinantnog fsh | |
| HRP20020480B1 (en) | Process for the purification of pharmacologically active proteins through cationic exchange chromatography | |
| SAKAI et al. | A unique specificity of a calcium activated neutral protease indicated in histone hydrolysis | |
| JP2017514803A (ja) | ゴナドトロピンの新規の精製方法 | |
| FI116526B (fi) | Menetelmä K-vitamiinista riippuvaisten proteiinien eristämiseksi ja puhdistamiseksi | |
| KR940019726A (ko) | 종양괴사인자- 알파 뮤테인 | |
| US11952399B2 (en) | Methods for purifying proteins | |
| PT96994A (pt) | Metodo para purificacao de hiv gp12o, de forma a proporcionar um glicopeptido | |
| CA2404155A1 (en) | Methods for purifying highly anionic proteins | |
| NO930428L (no) | Proteinstrukturen til plantetoksingelonin | |
| EP0720618A1 (en) | Process for the purification of basic fibroblast growth factor | |
| DE19880004D2 (de) | Rekombinante Fusionsproteine auf der Basis Ribosomen-inaktivierender Proteine der Mistel Viscum album | |
| WO2011151716A1 (en) | Process for the purification of recombinant human il-11 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |